Ignite Creation Date:
2024-05-05 @ 11:23 AM
Last Modification Date:
2024-10-26 @ 9:06 AM
Study NCT ID:
NCT00024544
Status:
COMPLETED
Last Update Posted:
2012-03-07
First Post:
2001-09-19
Brief Title:
Pilot Study in Patients With Symptomatic Steroid-Naive Asthma
Sponsor:
Facet Biotech
Organization:
Facet Biotech
Study Overview
Official Title:
A Phase III Randomized Double-Blind Placebo-Controlled Parallel-Group Pilot Study of SB 240683 in Patients With Symptomatic Steroid-Naive Asthma
Status:
COMPLETED
Status Verified Date:
2012-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to evaluate an investigational medication to treat chronic asthma The research is being conducted at 20 clinical research sites in the US and is open to both men and women ages 18 to 70 years Participants in the study will have a number of visits to a research site over an 8-month period All study-related care and medication is provided to qualified participants at no cost This includes all visits examinations and laboratory work
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None